Efficacy of menatetrenone (vitamin k2) against non-vertebral and hip fractures in patients with neurological diseases: Meta-analysis of three randomized, controlled trials

Jun Iwamoto, Hideo Matsumoto, Tsuyoshi Takeda

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background and objective: Patients with neurological diseases such as Alzheimer's disease, stroke and Parkinson's disease have been reported to have vitamin K deficiency secondary to malnutrition, which increases the risk of non-vertebral and hip fractures. The purpose of the present study was to clarify the efficacy of menatetrenone (vitamin K2) against non-vertebral and hip fractures in patients with neurological diseases. Methods: A literature search was conducted on PubMed from January 1995 to July 2008 to identify randomized controlled trials (RCTs) of use of menatetrenone against non-vertebral and hip fractures in patients with neurological diseases. A meta-analysis of all RCTs meeting these criteria was then performed. Results: Three RCTs of patients with Alzheimer-disease (n = 178, mean age 78 years), stroke (n = 99, mean age 66 years) and Parkinson's disease (n = 110, mean age 72 years) met the criteria for meta-analysis. These RCTs did not include placebo controls but did have non-treatment controls. According to the meta-analysis, the overall relative risks (95% confidence intervals) for non-vertebral and hip fractures with menatetrenone treatment compared with non-treatment were 0.13 (0.05, 0.35) and 0.14 (0.05, 0.43), respectively, in patients with neurological diseases. No severe adverse events were reported with menatetrenone treatment. Conclusion: The present meta-analysis of three RCTs suggests that there is efficacy for menatetrenone treatment against non-vertebral and hip fractures among patients with neurological diseases. Further larger placebo-controlled trials are needed to confirm the results of the present study.

Original languageEnglish
Pages (from-to)471-479
Number of pages9
JournalClinical Drug Investigation
Volume29
Issue number7
DOIs
Publication statusPublished - 2009

Fingerprint

Vitamin K 2
Hip Fractures
Meta-Analysis
Randomized Controlled Trials
Parkinson Disease
Alzheimer Disease
Stroke
Vitamin K Deficiency
Placebos
PubMed
Malnutrition
menatetrenone
Confidence Intervals
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Efficacy of menatetrenone (vitamin k2) against non-vertebral and hip fractures in patients with neurological diseases : Meta-analysis of three randomized, controlled trials. / Iwamoto, Jun; Matsumoto, Hideo; Takeda, Tsuyoshi.

In: Clinical Drug Investigation, Vol. 29, No. 7, 2009, p. 471-479.

Research output: Contribution to journalArticle

@article{18445b7835334930ba04ac0a6d4b47dd,
title = "Efficacy of menatetrenone (vitamin k2) against non-vertebral and hip fractures in patients with neurological diseases: Meta-analysis of three randomized, controlled trials",
abstract = "Background and objective: Patients with neurological diseases such as Alzheimer's disease, stroke and Parkinson's disease have been reported to have vitamin K deficiency secondary to malnutrition, which increases the risk of non-vertebral and hip fractures. The purpose of the present study was to clarify the efficacy of menatetrenone (vitamin K2) against non-vertebral and hip fractures in patients with neurological diseases. Methods: A literature search was conducted on PubMed from January 1995 to July 2008 to identify randomized controlled trials (RCTs) of use of menatetrenone against non-vertebral and hip fractures in patients with neurological diseases. A meta-analysis of all RCTs meeting these criteria was then performed. Results: Three RCTs of patients with Alzheimer-disease (n = 178, mean age 78 years), stroke (n = 99, mean age 66 years) and Parkinson's disease (n = 110, mean age 72 years) met the criteria for meta-analysis. These RCTs did not include placebo controls but did have non-treatment controls. According to the meta-analysis, the overall relative risks (95{\%} confidence intervals) for non-vertebral and hip fractures with menatetrenone treatment compared with non-treatment were 0.13 (0.05, 0.35) and 0.14 (0.05, 0.43), respectively, in patients with neurological diseases. No severe adverse events were reported with menatetrenone treatment. Conclusion: The present meta-analysis of three RCTs suggests that there is efficacy for menatetrenone treatment against non-vertebral and hip fractures among patients with neurological diseases. Further larger placebo-controlled trials are needed to confirm the results of the present study.",
author = "Jun Iwamoto and Hideo Matsumoto and Tsuyoshi Takeda",
year = "2009",
doi = "10.2165/00044011-200929070-00005",
language = "English",
volume = "29",
pages = "471--479",
journal = "Clinical Drug Investigation",
issn = "1173-2563",
publisher = "Adis International Ltd",
number = "7",

}

TY - JOUR

T1 - Efficacy of menatetrenone (vitamin k2) against non-vertebral and hip fractures in patients with neurological diseases

T2 - Meta-analysis of three randomized, controlled trials

AU - Iwamoto, Jun

AU - Matsumoto, Hideo

AU - Takeda, Tsuyoshi

PY - 2009

Y1 - 2009

N2 - Background and objective: Patients with neurological diseases such as Alzheimer's disease, stroke and Parkinson's disease have been reported to have vitamin K deficiency secondary to malnutrition, which increases the risk of non-vertebral and hip fractures. The purpose of the present study was to clarify the efficacy of menatetrenone (vitamin K2) against non-vertebral and hip fractures in patients with neurological diseases. Methods: A literature search was conducted on PubMed from January 1995 to July 2008 to identify randomized controlled trials (RCTs) of use of menatetrenone against non-vertebral and hip fractures in patients with neurological diseases. A meta-analysis of all RCTs meeting these criteria was then performed. Results: Three RCTs of patients with Alzheimer-disease (n = 178, mean age 78 years), stroke (n = 99, mean age 66 years) and Parkinson's disease (n = 110, mean age 72 years) met the criteria for meta-analysis. These RCTs did not include placebo controls but did have non-treatment controls. According to the meta-analysis, the overall relative risks (95% confidence intervals) for non-vertebral and hip fractures with menatetrenone treatment compared with non-treatment were 0.13 (0.05, 0.35) and 0.14 (0.05, 0.43), respectively, in patients with neurological diseases. No severe adverse events were reported with menatetrenone treatment. Conclusion: The present meta-analysis of three RCTs suggests that there is efficacy for menatetrenone treatment against non-vertebral and hip fractures among patients with neurological diseases. Further larger placebo-controlled trials are needed to confirm the results of the present study.

AB - Background and objective: Patients with neurological diseases such as Alzheimer's disease, stroke and Parkinson's disease have been reported to have vitamin K deficiency secondary to malnutrition, which increases the risk of non-vertebral and hip fractures. The purpose of the present study was to clarify the efficacy of menatetrenone (vitamin K2) against non-vertebral and hip fractures in patients with neurological diseases. Methods: A literature search was conducted on PubMed from January 1995 to July 2008 to identify randomized controlled trials (RCTs) of use of menatetrenone against non-vertebral and hip fractures in patients with neurological diseases. A meta-analysis of all RCTs meeting these criteria was then performed. Results: Three RCTs of patients with Alzheimer-disease (n = 178, mean age 78 years), stroke (n = 99, mean age 66 years) and Parkinson's disease (n = 110, mean age 72 years) met the criteria for meta-analysis. These RCTs did not include placebo controls but did have non-treatment controls. According to the meta-analysis, the overall relative risks (95% confidence intervals) for non-vertebral and hip fractures with menatetrenone treatment compared with non-treatment were 0.13 (0.05, 0.35) and 0.14 (0.05, 0.43), respectively, in patients with neurological diseases. No severe adverse events were reported with menatetrenone treatment. Conclusion: The present meta-analysis of three RCTs suggests that there is efficacy for menatetrenone treatment against non-vertebral and hip fractures among patients with neurological diseases. Further larger placebo-controlled trials are needed to confirm the results of the present study.

UR - http://www.scopus.com/inward/record.url?scp=67650333861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650333861&partnerID=8YFLogxK

U2 - 10.2165/00044011-200929070-00005

DO - 10.2165/00044011-200929070-00005

M3 - Article

C2 - 19499964

AN - SCOPUS:67650333861

VL - 29

SP - 471

EP - 479

JO - Clinical Drug Investigation

JF - Clinical Drug Investigation

SN - 1173-2563

IS - 7

ER -